Video

Dr. Singal on the Importance of Early Diagnosis in HCC

Amit G. Singal, MD, discusses the importance of early diagnosis for patients with hepatocellular carcinoma.

Amit G. Singal, MD, associate professor, UT Southwestern Medical Center, discusses the importance of early diagnosis for patients with hepatocellular carcinoma (HCC).

There have been several advances with locoregional and systemic therapies in HCC, says Singal. However, early identification and diagnosis remains a key component in the management of these patients.

Patients with early-stage HCC should be referred to a transplant center to determine whether or not they are eligible for surgical resection or liver transplant, explains Singal.

Though checkpoint inhibitors have improved survival for patients, they are associated with a risk of transplant rejection, says Singal. As such, transplant eligibility should be determined before beginning systemic therapy, concludes Singal.

Related Videos
Binod Dhakal, MD
Jill Corre, PharmD, PhD
Saad Z. Usmani, MD, MBA, FACP, FASCO
Ashraf Z. Badros, MBCHB
Ruihua Xu, MD, PhD, professor, medical oncology, Department of Medical Oncology, president, Sun Yat-sen University Cancer Center, chairman, Chinese Society of Clinical Oncology
Thierry Andre, MD, professor, medical oncology, Sorbonne Université; head, Medical Oncology Department, Saint Antoine Hospital
Sanjay Popat, BSc, MBBS, FRCP, PhD, consultant medical oncologist, The Royal Marsden Hospital; professor, thoracic oncology, the Institute of Cancer Research
Toni Choueiri, MD, director, Lank Center for Genitourinary Oncology, co-leader, kidney cancer program, Dana-Farber Cancer Institute; Jerome and Nancy Kohlberg Chair, professor, medicine, Harvard Medical School
Angeles A. Secord, MD, MHSc, professor, obstetrics and gynecology, Duke Cancer Institute, discusses findings from the phase 2 PICCOLO trial (NCT05041257) investigating mirvetuximab soravtansine-gynx (Elahere) in patients with recurrent, platinum-sensitive ovarian cancer with high folate receptor alpha (FRα) expression.
Nancy U. Lin, MD, associate chief, Division of Breast Oncology, Susan F. Smith Center for Women’s Cancers, director, Metastatic Breast Cancer Program, director, Program for Patients with Breast Cancer Brain Metastases, Dana-Farber Cancer Institute; professor, medicine, Harvard Medical School